Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQHJTF)

Drug Name

Green tea Drug Info

Synonyms

Oxotremorine; Oxytremorine; Oxotremorin; Tremorine, oxo-; 70-22-4; 2'-Oxopyrrolidino-1-pyrrolidino-4-butyne; MLS000766260; UNII-5RY0UWH1JL; EINECS 200-728-0; 5RY0UWH1JL; NSC 330497; 1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one; BRN 1530948; CHEMBL7634; 1-(4-(Pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one; CHEBI:7851; 2-PYRROLIDINONE, 1-(4-(1-PYRROLIDINYL)-2-BUTYNYL)-; RSDOPYMFZBJHRL-UHFFFAOYSA-N; 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-; Tocris-0843; Spectrum_001875; Spectrum_001448; AC1L1ILJ; Spectrum5_001099

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4630
ChEBI ID: CHEMBL7634
CAS Number: CAS 70-22-4
TTD Drug ID: DMQHJTF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Muscarinic acetylcholine receptor M2 (CHRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[4]
Methacholine Chloride	DMGS4QH	Asthma	CA23	Approved	[5]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[6]
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[7]
Gallamine Triethiodide	DMPO0MS	Stabilize muscle contraction	FB3Z	Approved	[8]
FP-1097	DMC1F2T	Urinary incontinence	MF50.2	Phase 2	[9]
PSD-506	DMT0KB1	Overactive bladder	GC50.0	Discontinued in Phase 2	[10]
Otenzepad	DMRXHAC	Heart failure	BD10-BD13	Discontinued in Phase 2	[11]
SCH-211803	DM92E0W	Parkinson disease	8A00.0	Discontinued in Phase 1	[12]
Alvameline	DMLN0Y5	Alzheimer disease	8A20	Terminated	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Squalene monooxygenase (SQLE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Naftifine	DMHVBG1	Dermatomycosis	EA60	Approved	[14]
Tolnaftate	DM28MU7	Dermatophytosis	1F28.2	Approved	[15]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[16]
FR-194738	DMNACIV	Hypercholesterolaemia	5C80.0	Terminated	[17]
SDZ-87-469	DMBY6CQ	Coronary artery disease	BA80	Terminated	[15]
NB-598	DMJVTQN	N. A.	N. A.	Terminated	[3]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[16]
1,2,3,4,6-penta-O-galloyl-beta-D-glucose	DMTK650	Discovery agent	N.A.	Investigative	[16]
Pedunculagin	DMKLRCX	Discovery agent	N.A.	Investigative	[16]
CORILAGIN	DMAC698	Discovery agent	N.A.	Investigative	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M2 (CHRM2)	TTYEG6Q	ACM2_HUMAN	Agonist	[2]
Squalene monooxygenase (SQLE)	TTE14XG	ERG1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 302).
2	Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93.
3	Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
4	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
5	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
6	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
7	Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
8	Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
9	Clinical pipeline report, company report or official report of FemmePharma.
10	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11	Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
12	Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
13	In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
14	Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
15	Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
16	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
17	Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7.